Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression

Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641

(2012) Douglas R. Strother et al.   JOURNAL OF CLINICAL ONCOLOGY

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

(2011) G Schleiermacher et al.   BRITISH JOURNAL OF CANCER

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

(2011) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Accumulation of Segmental Alterations Determines Progression in Neuroblastoma

(2010) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

(2010) David L. Baker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

(2009) Isabelle Janoueix-Lerosey et al.   JOURNAL OF CLINICAL ONCOLOGY